ASPIRE
24 evidence topics · 15 sources
Objective
Registry objective and official title
Regulatory purpose: safety data to support a label for patients aged 2 years and older
Location and study date
Registry record: dates, status, and sites
| Field | Quoted record |
|---|---|
| Protocol number | “TSHA-102-CL-201” |
| Study start | “2026-05-08” |
| Primary completion (estimated) | “2031-06” |
| Overall status | “Active, not recruiting” |
| Site | “University of Alabama at Birmingham” |
| Site | “Rush University Medical Center” |
| Site | “Boston Children's Hospital” |
Enrollment across multiple sites and dosing timeline
Study design
Single-group, open-label phase 3 design with blinded central raters
Extrapolation design: efficacy from REVEAL pivotal, safety from ASPIRE
Eligibility criteria
Inclusion criteria
Treatment
Single intrathecal dose adjusted for brain volume
High dose scaled to the lower brain volume of children aged 2 to less than 4 years
Study outcomes
Rationale for using treatment-emergent adverse events as the primary endpoint
Primary endpoint: treatment-emergent adverse events through week 25
Safety data requirement agreed with the FDA
Spontaneous milestone gain before 6 years of age limits efficacy assessment
Regulatory framework: pediatric extrapolation and additional safety data
Statistical analysis description
Number of participants (Planned and analyzed)
Planned enrollment of three participants, overenrolled to four
Description of analysis sets
No evidence found.
Results
Participant disposition
All participants past the acute post-dosing monitoring period
Baseline characteristics
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Pooled safety across REVEAL Phase 1/2, REVEAL pivotal, and ASPIRE as of November 2026
Study limitations
Summary
- ASPIRE is a multicenter, open-label study in which every participant receives TSHA-102. It dosed 4 participants (3 planned) aged 2 to less than 4 years, and the registry lists 3 sites.
- The registry primary endpoint is the proportion of participants experiencing any treatment-emergent adverse events and serious adverse events from baseline through week 25. The planned BLA is to include a minimum of 3 months of ASPIRE safety data, which is shorter than the 25-week primary safety analysis period and the 5-year follow-up period.
- No ASPIRE-specific safety results have been reported. The available safety statement pools 33 participants across REVEAL Phase 1/2 (12), REVEAL pivotal (17), and ASPIRE (4) and reports the absence of severe treatment-related serious adverse events and dose-limiting toxicities as of the November 2026 data cutoff; it does not report the type or frequency of other adverse events in the 4 ASPIRE participants.
- No efficacy results have been reported. Efficacy in children aged 2 to less than 6 years is to be extrapolated from REVEAL pivotal participants aged 6 to less than 22 years in the developmental plateau population. The natural history analysis reports spontaneous first-time gain of a single milestone as high as 97% before 6 years of age, and states that including younger participants without explicit age accounting could increase background spontaneous gain.
- None of the three trials has dosed children aged 4 to less than 6 years: ASPIRE enrolls children aged 2 to less than 4 years, the 12 REVEAL Part A participants were 6 to 21 years of age at dosing, and REVEAL pivotal enrolls participants aged 6 to less than 22 years.
- The dose is 1.0 × 10¹⁵ total vector genomes adjusted for brain volume; no description of the scaling method or of the doses administered was identified.
- The registry states that other protocol-defined inclusion and exclusion criteria may apply, and no published protocol, statistical analysis plan, or description of analysis sets was identified.
- All information comes from the sponsor's registry record, press releases, and SEC filings and from a natural history analysis. The company's August 2026 corporate presentation describes efficacy data for females aged 2 to less than 4 years as to be extrapolated from the pivotal trial, while the Form 10-K and the third quarter 2026 Form 10-Q describe extrapolation to the 2 to less than 6-year-old population.